PMID- 22463973
OWN - NLM
STAT- MEDLINE
DCOM- 20130312
LR  - 20181202
IS  - 1532-8171 (Electronic)
IS  - 0735-6757 (Linking)
VI  - 30
IP  - 9
DP  - 2012 Nov
TI  - A randomized controlled trial of adding intravenous pantoprazole to conventional 
      treatment for the immediate relief of dyspeptic pain.
PG  - 1737-42
LID - S0735-6757(12)00057-5 [pii]
LID - 10.1016/j.ajem.2012.02.001 [doi]
AB  - INTRODUCTION: Acute, severe dyspeptic pain is a common condition in the emergency 
      department. Despite the traditional "GI cocktail" (GI indicates 
      gastrointestinal), an intravenous (IV) proton pump inhibitor (PPI), a novel 
      acid-lowering drug, has recently been used to treat this condition. The aim of 
      this study was to evaluate the immediate effect of IV pantoprazole in addition to 
      the conventional GI cocktail in the relief of severe dyspeptic pain. METHODS: 
      This double-blind, randomized, controlled study was conducted in the emergency 
      department of an urban tertiary-care hospital from January 2011 to October 2011. 
      Selected patients with severe dyspeptic pain were randomized to treatment with a 
      placebo, antacid, and antispasmodic (conventional group) or IV pantoprazole, 
      antacid, and antispasmodic (pantoprazole group). The self-reported 100-mm visual 
      analog scale score, adverse effects, and overall satisfaction were evaluated in 
      15-minute intervals for 60 minutes. RESULTS: Eighty-seven eligible cases were 
      enrolled in the study. Forty-four and 43 patients were randomized in the 
      conventional group and pantoprazole group, respectively. There was no difference 
      in the mean 60-minute visual analog scale scores between the treatment groups. 
      The rate of "responders," additional drug use, adverse effects, and patient 
      satisfaction were similar between the groups. CONCLUSION: Intravenous PPI 
      provides no additional benefit over the conventional GI cocktail in the relief of 
      acute, severe dyspeptic pain. Because of its neutral effect and higher cost, the 
      use of IV PPI to treat such conditions should be discouraged in general clinical 
      practice.
CI  - Crown Copyright (c) 2012. Published by Elsevier Inc. All rights reserved.
FAU - Musikatavorn, Khrongwong
AU  - Musikatavorn K
AD  - Emergency Medicine Unit, Department of Medicine, Faculty of Medicine, 
      Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross 
      Society, Bangkok 10330, Thailand. kmusikatavorn@yahoo.com
FAU - Tansangngam, Ploykaew
AU  - Tansangngam P
FAU - Lumlertgul, Suthaporn
AU  - Lumlertgul S
FAU - Komindr, Atthasit
AU  - Komindr A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120329
PL  - United States
TA  - Am J Emerg Med
JT  - The American journal of emergency medicine
JID - 8309942
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - D8TST4O562 (Pantoprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*therapeutic use
MH  - Acute Pain/drug therapy/etiology
MH  - Adult
MH  - Anti-Ulcer Agents/administration & dosage/*therapeutic use
MH  - Double-Blind Method
MH  - Dyspepsia/complications/*drug therapy
MH  - Emergency Service, Hospital
MH  - Heartburn/drug therapy/etiology
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Pain Management/*methods
MH  - Pain Measurement
MH  - Pantoprazole
EDAT- 2012/04/03 06:00
MHDA- 2013/03/13 06:00
CRDT- 2012/04/03 06:00
PHST- 2011/11/15 00:00 [received]
PHST- 2012/01/30 00:00 [revised]
PHST- 2012/02/01 00:00 [accepted]
PHST- 2012/04/03 06:00 [entrez]
PHST- 2012/04/03 06:00 [pubmed]
PHST- 2013/03/13 06:00 [medline]
AID - S0735-6757(12)00057-5 [pii]
AID - 10.1016/j.ajem.2012.02.001 [doi]
PST - ppublish
SO  - Am J Emerg Med. 2012 Nov;30(9):1737-42. doi: 10.1016/j.ajem.2012.02.001. Epub 
      2012 Mar 29.